Interlaboratory Variation in Factor VIII:C Inhibitor Assay Results Is Sufficient to Influence Patient Management: Data from the UK National Quality External Assessment Scheme for Blood Coagulation

ABSTRACT

We report the results of external quality assessment exercises in which 60 to 120 centers performed factor VIII (FVIII) inhibitor testing on a series of samples over a 13-year period. Samples from seven different subjects were distributed for analysis comprising the following: four different subjects with severe hemophilia A with antibodies following replacement therapy, one subject with acquired hemophilia A and antibodies to FVIII, one subject with normal FVIII and an easily detected lupus anticoagulant, and one subject with mild hemophilia A and a difficult-to-detect lupus anticoagulant but without antibodies to FVIII. In all of the surveys the results obtained in different centers analyzing the same sample varied to an extent that would influence patient management decisions. In the UK National External Quality Assessment Scheme surveys reported here, there was considerable interlaboratory variation in the results of FVIII inhibitor testing that did not improve over the survey period. The coefficient of variation of results in different centers was between 33% and 106% in samples from patients with severe congenital hemophilia A. In some cases, results were affected by assay components. For one plasma, the mean FVIII inhibitor results in centers using one source of normal plasma was 3.9 Bethesda unit (BU)/mL compared with a mean of 5.7 BU/mL in centers using a different normal plasma source (p = 0.04). Our data indicate that the detection of FVIII inhibitors is not the same in different centers, and the degree of variability noted makes it likely that assay variability has contributed to the lack of international consensus in relation to the real incidence of FVIII inhibitors in different clinical settings. Improvements in assay standardization are urgently needed.

KEYWORDS

FVIII inhibitor - quality assurance

REFERENCES

• 1 McMillan C W, Shapiro S S, Whitehurst D, Hoyer L W, Rao A V, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors.  Blood. 1988;  71(2) 344-348
• 2 Ehrenforth S, Kreuz W, Scharrer I et al.. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.  Lancet. 1992;  339(8793) 594-598
• 3 Rasi V, Ikkala E. Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome.  Br J Haematol. 1990;  76(3) 369-371
• 4 Addiego J, Kasper C, Abildgaard C et al.. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.  Lancet. 1993;  342(8869) 462-464
• 5 Lusher J M, Arkin S, Abildgaard C F, Schwartz R S. Recombinant factor VIII for the treatment of previously untreated patients with haemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.  N Engl J Med. 1993;  328 453-459
• 6 Kasper C, Aledort L, Counts R et al.. Letter: A more uniform measurement of factor VIII inhibitors.  Thromb Diath Haemorrh. 1975;  34(3) 869-872
• 7 Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability.  Thromb Haemost. 1995;  73(2) 247-251
• 8 Giles A R, Verbruggen B, Rivard G E, Teitel J, Walker I. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis . A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada.  Thromb Haemost. 1998;  79(4) 872-875
• 9 Rubinger M, Lillicrap D, Rivard G E et al.. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.  Haemophilia. 2008;  14 281-286
• 10 Peerschke E I, Castellone D D, Ledford-Kraemer M, Van Cott E M, Meijer P. NASCOLA Proficiency Testing Committee . Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience.  Am J Clin Pathol. 2009;  131(4) 552-558
• 11 Parker E T, Craddock H N, Barrow R T, Lollar P. Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII.  J Thromb Haemost. 2004;  2(4) 605-611
• 12 Kitchen S, Walker I D, Woods T A, Preston F E. Thromboplastin related differences in the determination of international normalised ratio: a cause for concern? Steering Committee of the UK National External Quality Assessment Scheme for Blood Coagulation.  Thromb Haemost. 1994;  72 426-429
• 13 Favaloro E J, Bonar R, Duncan E RCPA QAP in Haematology Haemostasis Committee et al. Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation.  Thromb Haemost. 2006;  96(1) 73-78
• 14 Hay C R, Brown S, Collins P W, Keeling D M, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.  Br J Haematol. 2006;  133 591-605
• 15 Gringeri A, Mannucci P M. Italian Association of Haemophilia Centres . Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors.  Haemophilia. 2005;  11(6) 611-619
• 16 Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E, Novákovà I. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors.  Thromb Haemost. 2001;  86(6) 1435-1439
• 17 Kazmi M A, Pickering W, Smith M P, Holland L J, Savidge G F. Acquired haemophilia A: errors in the diagnosis.  Blood Coagul Fibrinolysis. 1998;  9(7) 623-628
• 18 Kitchen S, McCraw A. Diagnosis of Haemophilia and Other Bleeding Disorders. Montreal, Quebec, Canada; The World Federation of Hemophilia; 2001 Available at: http://www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Lab_manual_web.pdf Accessed December 7, 2009
• 19 Biggs R, Austen D E, Denson K W, Rizza C R, Borrett R. The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs.  Br J Haematol. 1972;  23 125-135
• 20 Biggs R, Austen D E, Denson K W, Borrett R, Rizza C R. The mode of action of antibodies which destroy factor VIII. II. Antibodies which give complex concentration graphs.  Br J Haematol. 1972;  23 137-155